Invest to Glow: A Stock Story That Started at the Dermatologist
Raise your hand if you've done Rejuran 🙋♀️
For years, Rejuran was THE skin booster in Korea. Salmon DNA, PDRN, skin regeneration — basically synonymous with the Korean skincare obsession. I got it regularly and loved the results. But somewhere along the way, a new name started popping up in my feed.
Re2O (Lituo).
"Wait, Is This Actually Selling?"
I didn't think much of it at first. Then I noticed L&C Bio's (290650 KS) stock quietly going parabolic. When the 12-month return hit +179%, I started paying attention. What are they making?
Turns out Re2O — formally called Elravie Re2O — was L&C Bio's newest product. A human collagen-derived skin booster. If Rejuran runs on PDRN (salmon-derived DNA), Re2O runs on collagen sourced from human tissue. And the price point? Around ₩600,000 per session. Nearly double what Rejuran costs.
So yes, the stock was moving. But was this thing actually selling?
I Just… Asked My Dermatologist
I'm the kind of person who goes straight to the source. So I asked the doctor at my regular clinic: "Are people doing Re2O a lot these days?"
At the time, they hadn't introduced it yet. But here's the funny part — after that conversation, the clinic actually added Re2O to their treatment menu 🤣
When I went back later and asked again, the response was honest:
"Some patients have had allergic reactions. And the price point is steep — Korean patients aren't jumping on it yet."
So then why was the stock still climbing? I'll be real — I had a moment of is this company just hyping themselves?
Then a Few Months Later, the Story Changed
I checked in again. The answer was completely different.
"Supply is actually tight right now. Clinics are having trouble getting stock."
Turns out Re2O had found its audience — not with domestic Korean patients, but with international medical tourists. The price that felt steep locally was being positioned abroad as "the best treatment, since you're already here." Meanwhile, exports to Singapore, Japan, and Southeast Asia were ramping up, with the company targeting ₩50bn in Re2O sales by 2026.
So What Is L&C Bio, Actually?
Founded 2011, listed on KOSDAQ in 2018. Their core business is human tissue products — processing donated skin, bone, cartilage, nerve tissue into transplantable materials. Their flagship product MegaDerm has been the long-standing cash cow.
Re2O is their 2024 entry into the aesthetics market. And MegaDerm Plus just received China NMPA approval in January 2025 — opening up a huge new market.
Here's Why I Find This Fun
My process usually starts with something I've personally experienced — a treatment I've seen trending, a conversation at the clinic — and then I go dig into the financials. When what I see in real life lines up with what the numbers are saying, that's when I get conviction.
Loved Rejuran → looked into Pharma Research. Heard Re2O was expensive but people were doing it anyway → looked into L&C Bio. Could I be wrong? Absolutely — the stock has already run hard, and timing matters. But finding investment ideas through daily life and genuine curiosity? Honestly, that's one of the things that makes this all worth it. 🤍
💉 Interested in finding clinics that offer Re2O? → Search on KBeauty Finder
📈 Want to track L&C Bio stock? → Invest to Glow
⚠️ This is not financial advice. All views are personal and based on public information only.